Curium Adds the Institut Laue-Langevin Reactor to Global Irradiation Portfolio to Ensure Continuous Supply of Lutetium-177 to Benefit More Than 100,000 Cancer Patients Over the Next 5 Years
June 05, 2024 05:27 ET
|
Curium
Curium partners with Institut Laue–Langevin to enhance Lutetium-177 supply, benefiting over 100,000 cancer patients in five years.
Curium Extends Irradiation Partnership With NRG I PALLAS in Netherlands for Continuous Supply of Lutetium-177 to Treat 1,000s of Cancer Patients Each Year
May 29, 2024 03:32 ET
|
Curium
PARIS, May 29, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that it has signed a long-term agreement to extend its current partnership with NRG I PALLAS for...
Canada Nuclear Medicine Market Analysis Report 2024-2030, Featuring Nordion, Lantheus Medical Imaging, Cardinal Health, Jubilant Life Sciences, Isologic Innovative Radiopharmaceuticals & Curium Pharma
January 24, 2024 05:46 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Canada Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostic, Therapeutic), Application (Oncology, Bone Metastasis,...
Nuclear Medicine Market to Surpass USD 24.20 Billion by 2030 Driven by Rising Prevalence of Chronic Diseases and Favorable Reimbursement Policies | Research by SNS Insider
December 13, 2023 09:01 ET
|
SNS Insider pvt ltd
Pune, Dec. 13, 2023 (GLOBE NEWSWIRE) -- “The Nuclear Medicine Market, as per the SNS Insider report, achieved a valuation of USD 9.24 billion in 2022. Anticipated to exhibit substantial growth, it...
Rafarma Pharmaceutical news update
November 30, 2023 09:30 ET
|
Rafarma Pharmaceuticals Inc.
Russia, Moscow, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA). The Company is pleased to announce that it has completed the restructuring, accounting and balance sheet...
Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule
November 23, 2023 07:47 ET
|
Curium
Curium, a global leader in nuclear medicine, announced today the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial.
Η CURIUM ΑΝΑΚΟΙΝΏΝΕΙ ΌΤΙ ΟΙ ΠΡΏΤΟΙ ΑΣΘΕΝΕΊΣ ΣΤΗΝ ΕΛΛΆΔΑ ΈΛΑΒΑΝ ΈΝΕΣΗ ΜΕ PYLCLARI® - ΈΝΑΝ ΚΑΙΝΟΤΌΜΟ ΙΧΝΗΘΈΤΗ PET 18F-PSMA ΠΟΥ ΕΝΔΕΊΚΝΥΤΑΙ ΣΕ ΑΣΘΕΝΕΊΣ ΜΕ ΚΑΡΚΊΝΟ ΤΟΥ ΠΡΟΣΤΆΤΗ
November 16, 2023 05:14 ET
|
Curium US LLC
ΠΑΡΙΣΙ, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Η Curium, παγκόσμιος ηγέτης στην πυρηνική ιατρική, ανακοίνωσε σήμερα ότι σε συνεργασία με τον αποκλειστικό διανομέα της SYN Innovation Laboratories στην...
Curium Announces First Patients in Europe Injected With PYLCLARI® – an Innovative 18F-PSMA Pet Tracer Indicated in Patients With Prostate Cancer
November 16, 2023 05:14 ET
|
Curium
PARIS, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that in partnership with its exclusive distributor SYN Innovation Laboratories in Greece, the...
Blackford and AIQ Solutions Announce Commercial Partnership to Bring Advanced Clinical Decision Support Tools for Metastatic Cancer to Healthcare Providers
November 14, 2023 09:00 ET
|
Blackford
Blackford and AIQ Solutions Announce Commercial Partnership to Bring Advanced Clinical Decision Support Tools for Metastatic Cancer to Healthcare Providers
Nuclear Medicine Market To Reach USD 46.3 Billion By 2032 Report By DataHorizzon Research
October 27, 2023 08:10 ET
|
DataHorizzon Research
Fort Collins, Colorado, Oct. 27, 2023 (GLOBE NEWSWIRE) -- According to DataHorizzon Research, the Nuclear Medicine Market size was valued at USD 8.1 Billion in 2022 and is expected to reach USD 46.3...